New clinical trial registered: BioVie Inc @BioVie_Pharma have launched a Phase 2 double-blind, randomized, placebo-controlled study of Bezisterim (aka NE3107, a ERK1/2 inhibitor) in 60 people with early #Parkinsons
#Parkinsons